If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Extreme UV (EUV or sometimes XUV) is characterized by a transition in the physics of interaction with matter. Wavelengths longer than about 30 nm interact mainly with the outer valence electrons of atoms, while wavelengths shorter than that interact mainly with inner-shell electrons and nuclei. The long end of the EUV spectrum is set by a prominent He+ spectral line at 30.4 nm. EUV is strongly absorbed by most known materials, but synthesizing multilayer optics that reflect up to about 50% of EUV radiation at normal incidence is possible. This technology was pioneered by the NIXT and MSSTA sounding rockets in the 1990s, and it has been used to make telescopes for solar imaging. See also the Extreme Ultraviolet Explorer satellite.
Abrams, J.L. Embalming. 2008. Chisholm, Hugh, ed. (1911). "Embalming" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Frederick, L.G.; Strub, Clarence G. [1959] (1989). The Principles and Practice of Embalming, 5th ed., Dallas, TX: Professional Training Schools Inc & Robertine Frederick. OCLC 20723376. Mayer, Robert G. (2000). Embalming: History, Theory and Practice, 3rd ed., McGraw-Hill/Appleton & Lange. ISBN 978-0-8385-2187-8. Schmitz-Esser, Romedio (2013). "Embalming and Dissecting the Corpse between East and West: From ar-Razi to Henry de Mondeville". In Classen, Albrecht (ed.). East Meets West in the Middle Ages and Early Modern Times: Transcultural Experiences in the Premodern World. Fundamentals of Medieval and Early Modern Culture. Vol. 14. Berlin and Boston: De Gruyter. pp. 611–624. doi:10.1515/9783110321517.611. ISBN 9783110328783. ISSN 1864-3396. Besouchet, Lídia (1993). Pedro II e o Século XIX (in Portuguese) (2nd ed.). Rio de Janeiro: Nova Fronteira. ISBN 978-85-209-0494-7. Rezzutti, Paulo (2019). D. Pedro II: a história não contada: O último imperador do Novo Mundo revelado por cartas e documentos inéditos (in Portuguese). Leya. ISBN 978-85-7734-677-6. https://www.dignityfunerals.co.uk/what-to-do-when-someone-dies/what-is-embalming/
=== Hybridisation and polyploidy === Like common wheat, spelt is a hexaploid wheat species, which means it has six sets of chromosomes. It is derived from a hybridisation event between a domesticated tetraploid wheat such as durum wheat and another wheat species, increasing the number of sets of chromosomes. Genetic evidence indicates an initial hybridisation of a domesticated tetraploid wheat and the diploid wild goat-grass Aegilops tauschii. It further shows that spelt could have arisen as the result of a second hybridisation, this time of bread wheat and emmer, giving rise to European spelt. The spelt genome continues to influence the breeding of modern hexaploid bread wheat through recent hybridisation.
Therefore, EHTs are suitable to model the disease phenotype and recapitulate functional alterations found in mice with hypertrophic cardiomyopathy. Another good system for modeling cardiomyopathies in the cell culture dish is the derivation of cardiac myocytes from iPSC. Reports of human iPSC models of sarcomeric cardiomyopathies showed cellular hypertrophy in most of the cases, including one with the c.2995_3010del MYBPC3 mutation that exhibited in addition to hypertrophy contractile variability in the presence of endothelin-1.
Geddy Lee's high-register vocal style has always been a signature of the band–and sometimes a focal point for criticism, especially during the early years of Rush's career when his vocals were high-pitched, with a strong likeness to other singers like Robert Plant of Led Zeppelin. A review in The New York Times opined that Lee's voice "suggests a munchkin giving a sermon". Although his voice has softened, it is often described as a "wail". His instrumental abilities, on the other hand are rarely criticized. He has cited Jeff Berlin, Jack Casady, John Entwistle, Jack Bruce and Chris Squire as being the bassists who had the biggest impact on his playing style. Lee's style, technique, and ability on the bass guitar have been influential to rock and heavy metal musicians, inspiring players including Steve Harris, John Myung, Les Claypool, and Cliff Burton. Lee is able to operate various pieces of instrumentation simultaneously during concerts, most evidently when he plays bass and keyboards, sings, and triggers foot pedals as in the song "Tom Sawyer".
Sources: en.wikipedia.org
Leucotomy was first undertaken in 1935 under the direction of the Portuguese neurologist (and inventor of the term psychosurgery) António Egas Moniz. First developing an interest in psychiatric conditions and their somatic treatment in the early 1930s, Moniz conceived a new opportunity for recognition in the development of a surgical intervention on the brain as a treatment for mental illness.
=== General information === Colombia at Britannica.com Lamoureux, Andrew Jackson; Edmundson, George (1911). "Colombia" . Encyclopædia Britannica. Vol. 6 (11th ed.). pp. 700–713. Official investment portal Official Colombia Tourism Website (in Spanish) National Administrative Department of Statistics
=== February === 1 February – A Statutory Instrument paving the way for the Northern Ireland Executive to be re-established is passed by the House of Commons. Conservative MP Mike Freer announces he is standing down from Parliament at the next election following death threats and an arson attack on his constituency office. Downing Street describes the situation as "an attack on democracy". Addressing a meeting of business leaders, Shadow Chancellor Rachel Reeves says that Labour would not increase corporation tax if elected, but may cut it to boost "competitiveness". Penny Mordaunt, the Leader of the House of Commons, has argued plans to expand the Senedd from 60 to 96 MSs would be the equivalent of expanding the House of Commons from 650 to 2,000 MPs. MP Christina Rees is readmitted to the Labour Party but announces her retirement at the next general election. 2 February – Senior Labour MP Darren Jones confirms that the party has ditched its commitment to spend £28bn a year on green investment schemes if it wins the next general election. 3 February – 2024 Northern Ireland Executive Formation: The Northern Ireland Assembly meets to elect a new Speaker. Edwin Poots, a former leader of the DUP, is chosen to be the Assembly's 7th Speaker. The Northern Ireland Executive is restored after the DUP ends its two year boycott; Sinn Féin's Michelle O'Neill is nominated as First Minister, becoming the first nationalist politician to hold the post, while the DUP's Emma Little-Pengelly is appointed deputy. SDLP MLA Matthew O'Toole is nominated as Leader of the Opposition.
Amylin analogues can both reduce energy intake and increase expenditure and can usefully be combined with leptin analogues for synergistic effect. The dual amylin and calcitonin receptor agonist cagrilintide, in combination with semaglutide, was more effective than semaglutide alone in promoting weight loss in clinical trials. Glucagon receptor agonists both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.
One way to effectively deal with the inherent multi-physics and the control systems development that is involved when including intelligent systems, is to adopt the V-Model approach to systems development, as has been widely used in the automotive industry for twenty years or more. In this V-approach, system-level requirements are propagated down the V via subsystems to component design, and the system performance is validated at increasing integration levels. Engineering of mechatronic systems requires the application of two interconnected "V-cycles": one focusing on the multi-physics system engineering (like the mechanical and electrical components of an electrically powered steering system, including sensors and actuators); and the other focuses on the controls engineering, the control logic, the software and realization of the control hardware and embedded software.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.